Purpose: To develop novel positron emission tomography (PET) agents for visualization and therapy monitoring of bacterial infections. Procedures: It is known that maltose and maltodextrins are energy sources for bacteria. Hence, 18 F-labelled maltose derivatives could be a valuable tool for imaging bacterial infections. We 
Introduction
A lthough there are significant developments in microbial biology, bacterial infections are on the rise throughout the world [1] . Due to poor diagnosis of bacterial infections and the development of drug resistance, bacterial infections continue to remain a significant cause of morbidity and mortality. It is important to distinguish bacterial infection from nonbacterial inflammation [2] . Although imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) provide excellent structural images, they are unable to discriminate these two conditions [3] . Molecular imaging modalities such as singlephoton emission computer tomography (SPECT) or positron emission tomography (PET) with suitable radiotracers allow the differential diagnoses of bacterial infections. Furthermore, SPECT and PET may be used for the early detection and monitoring of the treatment with antibiotics. Ciprofloxacin is a very effective antibiotic which is active against Gram-positive and Gram-negative bacteria. 18 F-Ciprofloxacin has been synthesized and evaluated for imaging bacterial infection. However, PET infection imaging in patients with [ 18 F]ciprofloxacin was unsuccessful [4, 5] . The use of 2-deoxy-2-[
18 F]fluoro-D-glucose ( 18 FDG) for imaging bacterial infection via glucose metabolism of activated white blood cell mechanism has been reviewed by Sasser et al. [6] and Petruzzi et al. [7] . However, 18 FDG imaging cannot distinguish infection from inflammation. 1-(2′-Deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-[
124 I]iodouracil (FIAU) is a very promising bacterial infection imaging candidate reported by Diaz et al. [8] . FIAU is a substrate for bacterial thymidine kinase. FIAU is also a substrate for mammalian mitochondrial thymidine kinase and results in nonspecific uptake in certain tissues. Ning et al. [9] reported fluorescent bacterial infection imaging probes named maltodextrin-based probes (MDPs). These probes made of maltohexose conjugated to fluorophore were able to detect as little as 10 5 CFU (colony forming unit) of bacteria. It is well known that maltose and maltodextrins are energy source for bacteria [10] . Maltose and maltodextrins are taken up by bacteria via the maltose transporter system which is not present in mammalian cells [11] . We therefore hypothesize that 18 Flabelled maltose derivatives would be ideal PET tracers for imaging bacterial infection.
Although the syntheses of 1-fluoromaltose [12-15] and 6-fluoromaltose [12, [16] [17] [18] (Fig. 1 ) has been described, the preparation of an 18 F-labelled fluoromaltose derivative has not been reported yet. Here, we report the synthesis of 4-O-(α-D-glucopyranosyl)-6-deoxy-6-
18 F]fluoromaltose, 11) as potential bacterial infection PET imaging agents and then perform pilot studies to show that 6-[
18 F]fluoromaltose is taken up by bacteria.
Materials and Methods

General
Chemicals were purchased from Sigma Aldrich (Milwaukee, WI). 6-Floro-and 1-fluoromaltose were synthesized according to literature procedures [12] [13] [14] [15] [16] [17] [18] (Fig. 1) . 6-[ 
18 F]fluoro-D-glucopranoside (10) (Scheme 3) were completed in the GE TRACER lab FX-FN synthesis module (GE Medical System, Milwaukee, WI).
A solution of 4′,6′-benzylidene-α-D-glucopyranosyl-D-glucopranoside [12, 16] (2,187 mg, 0.43 mmol) in dry pyridine (1.5 ml) containing trityl chloride (184 mg, 0.66 mmol) was .
Compound 3 (76 mg, 0.086 mmol) in 2 ml of aqueous acetic acid (80 % in water) was stirred for 75 min at 45°C [19] . The mixture was concentrated under vacuum and the crude benzylidene 4 purified by column chromatography (silica gel) using 94:6 chloroform and methanol (90 % in water) as the eluent to afford 34 mg (62 %) of 4 as colorless viscous oil with α/β=1.1/1. α-Anomer, (5) 4-Nitrophenylsulfonyl chloride (98 mg, 0.442 mmol) was added to a solution of 4 (54 mg, 0.084 mmol) in CH 2 Cl 2 (1.0 ml) containing triethylamine (84 μl) [20] . The mixture was stirred for 70 min at 0-5°C and concentrated under vacuum. The crude nosylate 5 was purified by column chromatography (silica gel) 
No-carrier-added [
18 F]fluoride trapped on a QMA cartridge was eluted with a solution of K 2 CO 3 (3.5 mg) and kryptofix 2.2.2 (15 mg) in water (0.1 ml) and acetonitrile (0.9 ml). The solvent was removed under vacuum at 65°C, and to the anhydrous residue was added a solution of nosylate precursor 5 (4-5 mg) in acetonitrile (0.8 ml). The mixture was heated for 10 min at 80°C. After cooling to room temperature, 10 ml of water was added and the solution passed through a light C-18 Sep-pak cartridge (Water) and Fig. 2 ) gave an Rf value of 0.5. The radio synthesis time was 120 min and the radiochemical yield was 5-8 % (decay-corrected).
Trifuorometanesulfonic anhydride (12 μl, 0.071 mmol) was added into a solution of 8 [12, 13] (40 mg, 0.063 mmol) in CH 2 Cl 2 (0.17 ml) containing pyridine (12 μl, 0.148 mmol) at 0-5°C. The mixture was stirred for 3 h at room temperature and diluted with 1.5 ml of CH 2 CL 2 . The CH 2 Cl 2 solution was successively washed with cold saturated NaHCO 3 (1.5 ml) and cold water (1.5 ml). The organic layer was dried (Na 2 SO 4 ) and concentrated under vacuum and the crude triflate 9 was purified by column chromatography (silica gel) using 1:1 ethyl acetate and hexane as the eluent to afford 14.5 mg (30 %) of 9 as colorless foam with α/β=1/3. α-Anomer, 1 
4-O-(α-D-
No-carrier-added [ 18 F]fluoride trapped on a QMA cartridge was eluted with a solution of K 2 CO 3 (3.5 mg) and kryptofix 2.2.2 (15 mg) in water (0.1 ml) and acetonitrile (0.9 ml). The solvent was removed under vacuum at 65°C, and to the anhydrous residue was added a solution of triflate precursor 9 (4-5 mg) in acetonitrile (0.8 ml). The mixture was heated for 10 min at 80°C. After cooling to room temperature, 10 ml of water was added and the solution passed through a light C-18 Sep-pak cartridge (Water) and the crude protected 1-[
18 F]fluoromaltose (10) eluted by passing 3 ml of acetonitrile trough the cartridge. The crude 10 was concentrated and hydrolyzed by 0.5 ml of 2 N NaOH in room temperature for 4 min to afford crude 1-[ 18 F]fluoromaltose 11. After addition of 1 ml of 1 N HCl, the neutral solution of 11 was injected onto a C18 reverse phase semipreparative HPLC column. The product 1-[
18 F]fluoromaltose (11) was collected at 7 min. After evaporation of solvent, it was reconstituted in saline. The radiochemical purity of 1-[ 18 F]fluoromaltose was determined by reverse phase analytical HPLC method and was more than 95 %. Also, radio-TLC of 11 (silica gel plate, CH 3 CN/H 2 O; 70:30) gave an Rf value of 0.46. The radio synthesis time was 110 min and the radiochemical yield was 4-6 % (decaycorrected).
Stability of 6-[ 18 F]Fluoromaltose in Serum
Serum (human or mouse) was centrifuged at 4°C, with speed of 13,000 rpm for 10 min. Supernatant (330 μl) was transferred to an Eppendorf vial containing 20 μl of formulated radiolabeled 6-[
18 F]fluoromaltose (50-100 μCi). For control, the same volume of radiolabeled compound in 330 μl phosphate-buffered saline (PBS) was used. After vortexing the radiolabeled mixtures, 70-μl aliquots were transferred to Eppendorf tubes and incubated at 37°C. At 14 C]maltose. The uptake studies were done in Hank's buffered saturated solution (HBSS) which has a physiological level of glucose (5 mM). All bacteria and cells were then washed in 1× PBS and lysed using a bacterial lysis solution (Bug Buster, EMD), and radioactivity of each well was determined by gamma counter for 18 F and liquid scintillation counting for 14 C samples. All experiments were performed in triplicate and uptake is expressed in percent uptake per microgram of protein. Statistical analyses were performed using GraphPad software. For blocking experiments, radiolabeled compounds were coincubated with 1 mM of maltose or 1 mM of 1-fluoromaltose. [20] at 0-5°C to afford 5 in 72 % yield. We applied synthesis of FDG precursor procedure [21] for synthesis of triflate 8. Scheme 3 shows the synthesis of 2,3,
Results
Chemistry
18 F]fluoromaltose precursor. Treatment of hepta-peracetyl-1-hydroxymaltose 8 [12, 13] with trifluoromethanesulfonic anhydride produced 9 in 30 % yield.
Radiochemistry
Fluorine-18-labeled maltose derivative 6 (Scheme 2) was prepared by nucleophilic displacement of the nosylate group in 5 by [
18 F]fluoride ion in acetonitrile at 80°C for 10 min. Initial purification of [ 18 F]6 was performed via a light C-18 Sep-pak cartridge. After passing the solution of [ 18 F]6 in acetonitrile through a light neutral alumina Sep-pack, it was concentrated and smoothly hydrolyzed by acid (1 N HCl) at 110°C for 10 min. After removal of the solvent under vacuum, the remaining acetyl groups in 6 were hydrolyzed by base (2 N NaOH) at room temperature for 4 min to yield 6-[
18 F]fluoromaltose 7. The radiochemical yield was 5-8 % (decay-corrected, n=8). Radio-TLC of 7 (Fig. 2) gave an Rf value of 0.5 which is identical to the Rf value of 6-fluoromaltose [12] under the same TLC condition. Likewise, 1-[
18 F]-labelled maltose derivative 10 (Scheme 3) was prepared by nucleophilic displacement of the triflate group in precursor 9 by [
18 F]fluoride ion in acetonitrile at 80°C for 10 min. 10 was purified by C-18 Sep-pak and de-protected with 2 N NaOH to afford
]fluoromaltose, 11). However, only the α-anomer was stable under the purification conditions. It has been reported that only the α-anomer of cold 1-fluoromatose is stable in room temperature [12] .
Stability of 6-[
F]Fluoromaltose in Serum
The percentage of intact 6-[ 18 F]fluoromaltose in PBS and human and mouse serum at 37°C was determined by HPLC. Figure 3 shows that the amount of intact 6-[
18 F]fluoromaltose decreased from 96 % at 1-h incubation to 65 % after 2 h. Also, one can determine the stability by using radio-TLC to demonstrate the presence of [
18 F]F − (Fig. 2) .
In Vitro Uptake Assays
To evaluate the ability of bacteria and cells to take up 6-[ 18 F]fluoromaltose (7), a strain of E. coli and a mammalian cell line (EL4) were exposed to 7. Figure 4 shows that the uptake of 7 by E. coli is time dependent. In EL4 cells, uptake was minimal after 60-min incubation with tracer. The uptake in E. coli could also be blocked by co-incubation with 1 mM of maltose, the natural substrate of the transporter (98 % blocking, pG0.0003). Likewise, 14 C-maltose uptake in 
Discussion
It has been reported that after intravenous injection of maltose in a human subject, maltose is slowly degraded in the lung with a limited urinary excretion [22] . The pharmacokinetics of a maltose-base PET tracer should be compatible with the clinical development. Therefore, 18 Flabelled maltose derivatives could be ideal PET tracers for imaging bacterial infections. It is difficult to predict which anomer of 1-substituted maltose has high affinity for bacteria. It is well known that the methyl alpha maltoside has higher affinity for bacteria than maltose [23] . In cells, glucose transporters (GLUTs) could be an issue by taking up 1-F-Gluc or 6-F-Gluc from in vivo metabolism of fluoromaltose and therefore increasing the background signal. The OH group at C6 seems to not make a hydrogen bond with GLUT1, and bulky substitutions at this position are tolerated. However, bulky substitutions at C1 are not tolerated [24] . So it makes sense to try first the 1-F-maltose to avoid a cellular uptake of 1-F-Gluc in case of in vivo metabolism. Unfortunately, this compound is not stable in vivo. The maltodextrin transporter in bacteria is more flexible and seems to be not very sensitive to substitution (9) .
Majority of fluorinated sugars are synthesized via DAST reagent. Due to difficult synthesis and long reaction time of F]fluoride ion in 4-6 % radiochemical yield (unoptimized, decay-corrected). However, only the α-anomer was stable under purification conditions. In fact, it has been reported that only the α-anomer of cold 1-fluoromaltose is stable in the room temperature [12] .
6-[
18 F]Fluoromaltose was sufficiently stable over the time necessary for PET studies (∼96 % intact compound after 1-h and ∼65 % after 2-h incubation in serum, Fig. 3) . The instability at the longer time could be due to slow defluorination of 6-[
18 F]fluoromaltose at 2 h. Figure 4 shows the uptake of 6-[ 18 F]fluoromaltose by E. coli and a mammalian cell line (EL4) and confirms that the uptake of 6-[
18 F]fluoromaltose in bacteria is time dependent. However, for EL4, the uptake was minimal after 60-min post-incubation with tracer. The uptake in E. coli could also be blocked by co-incubation with 1 mM of cold maltose (98 % blocking, pG0.0003), the natural substrate of the transporter. The rapid uptake is necessary if 6-[
18 F]fluoromaltose with an isotope half-life of 110 min is eventually going to prove efficacious as a PET tracer. The uptake studies were done in Hank's buffered saturated solution (HBSS) which has physiological levels of glucose (5 mM). So we are accounting for the presence of glucose in our tracer uptake studies. In vivo, the tracer will compete with glucose (mice could have been fasted before in vivo imaging to limit glycemia variation), but glucose will probably not saturate the maltodextrin transporter in bacteria. More biological data including in vivo studies of 6-[
18 F]fluoromaltose have been reported by us [25] . Also, we tested 1-fluoromaltose in a competition assay as shown in Fig. 5 . This suggested that 1-fluoromaltose was recognized and transported by the bacteria in a manner identical to maltose itself. However, we found that α-anomer of 1-[
18 F]fluoromaltose is not stable in vivo and de-fluorinated rapidly which resulted in high uptake of [ 18 F]fluoride ion by the bones (data not shown).
Conclusion
We have successfully synthesized both 6-and 1-[
18 F]fluoromaltose via a direct fluorination of an appropriate protected maltose precursor. Preliminary bacteria uptake experiments done in E. coli bacteria suggest possible applicability of 6-[
18 F]fluoromaltose as a new PET imaging agent for detection and monitoring of disease of bacterial infection origin. In the future, we will further examine tracer uptake and metabolism in bacteria and determine the efficacy of 6-[
18 F]fluoromaltose in imaging bacterial infection for various mouse models. These data should lay a foundation for the use of 6-[
18 F]fluoromaltose as an imaging agent in human bacterial infection disease.
